ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 962

Role of Syndecans in Cytokine Mediated Inflammation in Rheumatoid Arthritis Synovial Fibroblasts

Solomon Agere1, Nahid Akhtar1, David Fox2 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Department of Medicine [Division of Rheumatology], University of Michigan Medical System, Ann Arbor, MI

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: adjuvant arthritis, cytokines, proteoglycans, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Syndecans (SDCs) are type-I transmembrane proteoglycans that prominently interact with heparan sulfate, extracellular matrix (ECM) components and glycoproteins. The present study was carried out to determine the role of syndecans in promoting tissue destruction mediated using human rheumatoid arthritis synovial fibroblasts (RASFs) and a rat adjuvant-induced arthritis (AIA) model of RA

Methods: Human RASFs and healthy (NL) SFs were isolated from de-identified RA and NL synovial tissues, respectively, under an IRB approved protocol. RASF and NLSF lysates were prepared to study the expression of SDC-1, SDC-2, SDC-3, and SDC-4 using qRT-PCR and Western immunoblotting. Knockdown of SDCs using siRNA approach was conducted to study its effect on IL-1β (10 ng/ml) or TNF-α (20 ng/ml) induced signaling pathways and downstream inflammatory mediators in RASFs. Ankle, heart, spleen and liver homogenates from naïve and AIA rats were analyzed for differences in the expression levels of SDCs. Serum levels of SDC-2 and SDC-4 were also analyzed in RA patients and in AIA rats. p<0.05 was considered significant.

Results: Our qRT-PCR results showed that the expression of SDC-2 (~320%) and SDC-4 (~80%) was significantly higher in RASFs when compared to NLSFs, which was also confirmed in protein levels using Western blotting method. No significant changes were observed in SDC-1 and SDC-3 expression in RASFs compared to NLSFs. Stimulation of RASFs with IL-1β or TNF-αinduced SDC-2 and SDC-4, but not SDC-1 or SDC-3, expression compared to the un-stimulated controls. Knockdown of SDC-2 and SDC-4 significantly inhibited IL-1β-induced matrix metalloproteinase-1 (MMP-1) and MMP-13 production, which could partly be due to the decrease in ERK and PKCδ activation in RASFs. In addition, we also observed a statistically significant decrease in IL-1β-induced IL-6 production with the knockdown of SDC-2 or SDC-4. Evaluation of the tissue homogenates from naïve and early (day 8) and established (day 18) AIA in rats for SDC expression showed a marked increase in SDC-2 and -4 expression in serum, ankles, liver, and spleen in AIA group at day 8 and at day 18 compared with naïve group. Treatment of methotrexate (MTX) significantly decreased both SDC-2 and -4 expression compared to the AIA alone group. However, human RA serum samples showed a consistent increase only in SDC-4 expression compared to the serum from healthy donors.

Conclusion: These findings suggest SDC-4 may be a potential therapeutic target in regulating the role of cytokines and MMPs in mediating tissue destruction in RA.


Disclosure: S. Agere, None; N. Akhtar, None; D. Fox, None; S. Ahmed, None.

To cite this abstract in AMA style:

Agere S, Akhtar N, Fox D, Ahmed S. Role of Syndecans in Cytokine Mediated Inflammation in Rheumatoid Arthritis Synovial Fibroblasts [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/role-of-syndecans-in-cytokine-mediated-inflammation-in-rheumatoid-arthritis-synovial-fibroblasts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-syndecans-in-cytokine-mediated-inflammation-in-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology